osimertinib
astrazeneca
['osimertinib']
goldman et al poster on met adc+osimertinib in patients with osimertinib resistance and met expression. orr 58%. #asco22 
Medical Oncologist at Memorial Sloan Kettering. Clinical focus on patients with lung & thymic cancers. COI: https://t.co/lXxGGb6HFw